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Nucleic acid aptamers, or simply aptamers, are oligonucleotides that bind specific ligands that vary from
small molecules to proteins. An aptamer for a specific ligand is routinely identified through the process of sys-
tematic evolution of ligands by exponential enrichment, although some aptamers are found in nature as
ligand-binding sites of special RNA structures called riboswitches. Aptamers have significant value in
biotechnology and for the development of aptamer-based therapeutics. This perspective briefly highlights
the tight connection between the journal Chemistry & Biology and in vitro selection technologies over the
past two decades. We then focus our discussion on the summary of the current state of the art of aptamer
technologies and provide our view of the future challenges and opportunities for the field.The launch of Chemistry & Biology in 1994 filled an important
gap. In the April 15, 1994, prelaunch issue, the founding editors
wrote, ‘‘It is the explosion of research at the interface of chemis-
try and biology.that hasmotivated us to provide a newoutlet for
research papers that should be read by researchers in both dis-
ciplines. At present, authors of such papers have the uncomfort-
able choice of publication in a chemical journal, which is rarely
read by biologists, or the reverse. Chemistry & Biology will aim
to be accessible to both sets of readers, and we will consider
the journal a success if it lowers the language barriers between
these two fields, which have so much to say to each other’’
(Schreiber and Nicolaou, 1994). Now, 20 years later, the journal
can definitely be considered a success, as it continues to publish
on research topics that are at the intersection of the two fields,
and centrally positioned within the scope of chemical biology,
a discipline that emerged at about the same time as the journal
and has since established itself.
Some of the highly interdisciplinary fields that have been rep-
resented in the journal from its inception are aptamer research,
the in vitro selection of functional nucleic acids, and systematic
evolution of ligands by exponential enrichment (SELEX). Indeed,
the journal quickly established itself as one of themost influential
places for publishing cutting-edge results in aptamer, SELEX,
ribozyme and riboswitch research and in the in vitro selection
of novel ribozymes, deoxyribozymes, and aptazymes, as dis-
cussed here and in a related perspective included in this issue
of Chemistry & Biology (Joyce and Breaker, 2014). Some of the
breakthroughs that were published in the pages of Chemistry &
Biology are the report of the first catalytic DNA, DNAzyme
(Breaker and Joyce, 1994); one of the first riboswitch papers
describing the coenzyme B12 riboswitch (Nahvi et al., 2002);
and the first crystal structure of a riboswitch (Serganov et al.,
2004). Additional notable early discoveries that remain relevant
to this day include a hemin-binding DNA aptamer; a G-quadru-
plex structure that exhibited peroxidase activity in the presence
of hemin (Travascio et al., 1998), which is now widely used as
a catalytic G-quadruplex reporter system; a famous in vitro
selected Diels-Alderase ribozyme (Seelig and Ja¨schke, 1999);
and other ribozymes, DNAzymes, and aptazymes that expanded
the scope of nucleic acid-catalyzed chemical transformations
(Carmi et al., 1996; Fusz et al., 2005; Jenne and Famulok,Chemistry & Biology 21998; Kim and Joyce, 2004; Levy and Ellington, 2002; Sengle
et al., 2001; Tang and Breaker, 1997; Wilson and Szostak,
1998; Zhang and Cech, 1998). Over the years, many other
aptamers, too many to list individually, have appeared in this
journal, forming a basis for further research and development,
including the development of therapeutic aptamers, such as
the 20-NH2-modified anti-VEGF aptamer (Green et al., 1995)
that was the first of a series of modified VEGF-binding aptamers
(Burmeister et al., 2005; Ruckman et al., 1998) leading to the
development of Macugen (the first clinically approved therapeu-
tic aptamer) and several aminoglycoside-binding aptamers (Lato
et al., 1995; Wallis et al., 1995; Wang and Rando, 1995).
Since the early days of aptamer research and in vitro selection,
the field has matured considerably and hundreds of laboratories
worldwide are now engaged in aptamer research in one way or
another, or they perform SELEX or in vitro evolution experiments.
As such, the development of aptamers and SELEX methodolo-
gies has gained tremendous attention within the past 20 years.
Because of their unique properties, aptamers are nowadays
used in many disciplines and different scientific fields, and for
a variety of purposes (Figure 1). For example, aptamers are
used as capture molecules (Mu¨ller et al., 2011), as genetically
encoded reporters (Paige et al., 2011), as building blocks for
nanoarchitectures and nanomotors (Zhu et al., 2013), and simply
as inhibitors of biological function (Keefe et al., 2010). The latter
is the most auspicious application, opening doors to a novel
macromolecular therapeutic class.
Aptamers can be synthesized chemically, and their sequence
information can be shared digitally as a blueprint for
manufacturing them. This allows cheap and fast production
with reproducible properties and very low, if any, batch-to-batch
variation. The majority of aptamers are currently used for
research purposes; hence either no modifications or convenient
fluorescent or affinity tags are required. In this way, commercial
suppliers synthesize and deliver aptamers upon the provision of
their sequences—quickly, cheaply, and at reasonable scales, as
simple as primer molecules. These features in particular mark
aptamers as unique and clearly set them apart from protein-
type macromolecules (e.g., antibodies or their derivatives).
Recent developments implement amino acid-like residues into
nucleic acid scaffolds (e.g., indole, benzyl, or alkyne moieties)1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1055
Figure 1. Applications of Aptamers
Aptamers (left) are advantageous to many other
molecules because they can be accessed syn-
thetically. This allows their expression in vivo and
in cells (middle, 1), their stabilization by chemical
modification (middle, 2), the derivatization of
sensor surfaces with aptamers (middle, 3), their
tagging with a huge variety of probes and anchor
molecules (middle, 4), and their immobilization on
various carriers and matrices (middle, 5). Conse-
quently, the fields of application of aptamers are
very broad, ranging from target validation, ther-
apy, and diagnosis to high-throughput screening
(HTS) and purification or separation (right).
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of the selection process (Ja¨ger et al., 2005) and thus allow
access to aptamers with chemically modified side chains
(Vaught et al., 2010). This approach has led to a tremendous
improvement of the success rate of SELEX experiments and to
aptamers with an incredibly low off-rate, reflected by the
acronym SOMAmers (slow off-rate modified aptamers). More
than 1,000 SOMAmers are now embedded in a diagnostic plat-
form, allowing the detection of variations in protein signatures,
along with distinct human pathologies (Gold et al., 2010).
Whether these aptamers also are valuable as therapeutics has
yet not been explored, but because of their sophisticated recog-
nition properties, there is virtually no doubt. However, pharma-
cokinetics, bioavailability, and toxicity must be explored first.
In this regard and besides ‘‘normal’’ aptamers, Spiegelmers
are the most developed therapeutic investigational new drugs
in the aptamer field (Hoellenriegel et al., 2014; Vater and Kluss-
mann, 2003). These aptamers consist of an L-enantiomeric1056 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reservedribose backbone and hence are almost
nuclease resistant. Recent promising
data raise the hope that this aptamer
class will provide effective therapies in
the near future.
Aptamer-based therapeutics are cer-
tainly the major long-sought desire to be
fulfilled. Besides Macugen, no other
aptamer has gained approval during the
past 10 years, but some are in advanced
stages of clinical trials. Among them the
aptamer-antidote pair targeting coagula-
tion factor IXa, identified in Bruce Sullen-
ger’s laboratory and now developed
further by Regado Biosciences (Rusconi
et al., 2004). Likewise, as therapeutics,
the field also is awaiting diagnostic
assays that advance from the proof-of-
concept stage toward routine clinical
applications. A first step into this direction
has been taken by the groups of Mayer
and Po¨tzsch, providing novel aptamer-
based diagnostic assay formats. These
enable the sensitive detection of active
thrombin and activated protein C (APC)
in patient samples (Mu¨ller et al., 2011,
2012), whereas the APC assay uses anaptamer that was first published in Chemistry & Biology (Mu¨ller
et al., 2009). Both assays are now commercially available in
ready-to-use kit formats provided by American Diagnostica.
Because we expect that the number of commercially available
aptamers will continue to grow over the next few years, in no
small part due to a steadily increasing number of companies
that offer fee-for-service-based identification of aptamers, the
number of detectable target molecule-aptamer pairs will
become significant. Commercialization of aptamer development
will allow access to these molecules by every interested
researcher, provided these services are affordable, are trans-
parent, and deliver sequence information and aptamers with
reproducible properties. This might form the foundation for wide-
spread aptamer use in a plethora of elaborated approaches. A
novel attention-getting branch is the identification of cell- or tis-
sue-specific series of aptamers. These are available by selection
procedures using living cells, bacteria, or subcellular prepara-
tions thereof as complex target structures. An advanced variant
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tumor-targeting aptamers de novo by an in vivo SELEX approach
(Mi et al., 2010). Fortunately, many cell-recognizing aptamers are
taken up by the targeted cells or tissues, although the underlying
molecular mechanisms are not very well understood as of yet.
However, these types of aptamers will provide a novel basis
for developing targeted therapies, especially as delivery vehicles
to transport macromoleular cargo therapeutics (e.g., small inter-
fering RNA molecules or antagomiR sequences into specific
cells (Pastor et al., 2010; Pofahl et al., 2014). Because themolec-
ular targets of such aptamers are unknown, this approach also
enables the identification of new biomarkers specifically associ-
ated with pathogenic tissue.
2014 and Beyond
Aptamers represent an interesting molecule class that is posi-
tioned between small molecules and biologicals. They have
matured considerably throughout the past two decades and
have become true alternative compounds in chemical biology
and biomedicine. Nevertheless, acceptance and use of ap-
tamers in industry and by (bio)pharmaceutical companies re-
mains rare and is certainly a gap that needs to be filled in the
near future. The question is, why is this the case, andwhat needs
to be done to convince companies to rely on this compound
class?
One unquestionable aspect is the low success rate (<30%) of
aptamer selection, compared with antibody development. This
will be overcome by using modified nucleotides in the selection
process or introducing entirely novel base pairs and building
blocks (Kimoto et al., 2013; Pinheiro et al., 2012). However,
methods to use these approaches are yet not widely available
but are limited to a few specialized groups. Advances in
sequencing technologies not only will enhance the success
rate of SELEX approaches but also will allow deep insight into
the governing evolutionary process that takes place during the
selection procedure. High-throughput sequencing has the po-
tential to revolutionize SELEX, as it makes it possible to scan
millions of sequences in a library simultaneously. From a mathe-
matical point of view, this provides tremendous output and
allows the depiction of sequences that are not overrepresented
in a library and are rare because of nonoptimized replication
behavior but still retain target-binding properties. Conventional
sequencing approaches will simply miss these aptamers.
In light of these recent advances, we believe that aptamer
selection and application will make as much improvement in
the coming 20 years as it did throughout the past 20. However,
to convince other researchers, industry, and clinicians of the
advantages of aptamers compared with other compound clas-
ses, quality standards need to be implemented to certify, secure,
and testify to aptamers’ properties. This could be realized by
establishing independent reference laboratories worldwide,
which perform interaction analyses of newly identified aptamers
and their cognate targets, essentially prior publication. This
endeavor will ensure that identified aptamers are actually doing
what they are supposed to do: binding with a certain affinity and
specificity to the initial target molecule. Because sequences can
be easily shared digitally, this approach will also verify sequence
identity and its functional relationship. An adequate certificate
can simply be included in every publication of a new aptamer,Chemistry & Biology 2confirming that this particular molecule showed activity also in
the hands of independent scientists. We are convinced that
this certification process will enhance confidence in aptamers
and avoid conflicts that are known from antibodies, which
because of batch-to-batch variation reveal diverse recognition
patterns, diverging from the supposed target molecule. This
becomes even more important, as several companies now offer
aptamer identification on a fee-for-service basis. Including third-
party validation of these aptamers will help secure a distinct level
of quality and reliability.
Taken together, the future of aptamer and in vitro selection
research continues to look bright, and journals such as Chemis-
try & Biology and others focused on chemical biology are well
placed to provide an excellent forum for the publication of the
most exciting results in this growing research field.
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